Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (GB:0J2O)
LSE:0J2O
Halozyme (0J2O) Share Price & Analysis
0 Followers
0J2O Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$30.09 - $58.68
Previous Close$38.25
Volume8.00
Average Volume (3M)286.00
Market Cap
$5.04B
Enterprise ValueN/A
Total Cash (Recent Filing)$348.27M
Total Debt (Recent Filing)$1.50B
Price to Earnings (P/E)N/A
Beta1.13
Next Earnings
Nov 07, 2023EPS Estimate
$0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding131,920,880
10 Day Avg. Volume104
30 Day Avg. Volume286
Standard Deviation0.09
R-Squared0.19
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)-6.53
Price to Sales (P/S)28.54
Price to Cash Flow (P/CF)19.00
P/FCF Ratio18.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$56.57Price Target Upside47.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Halozyme News
Pre-EarningsHALO Upcoming Earnings Report: What to Expect?
0J2O FAQ
What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest share price was $30.09 and its highest was $58.67 in the past 12 months.
What is Halozyme Therapeutics’s market cap?
Currently, no data Available
When is Halozyme Therapeutics’s upcoming earnings report date?
Halozyme Therapeutics’s upcoming earnings report date is Nov 07, 2023 which is in 38 days.
How were Halozyme Therapeutics’s earnings last quarter?
Halozyme Therapeutics released its earnings results on Aug 08, 2023. The company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.11.
Is Halozyme Therapeutics overvalued?
According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued.
Does Halozyme Therapeutics pay dividends?
Halozyme Therapeutics does not currently pay dividends.
What is Halozyme Therapeutics’s EPS estimate?
Halozyme Therapeutics’s EPS estimate is $0.75.
How many shares outstanding does Halozyme Therapeutics have?
Currently, no data Available
What happened to Halozyme Therapeutics’s price movement after its last earnings report?
Halozyme Therapeutics reported an EPS of $0.74 in its last earnings report, beating expectations of $0.63. Following the earnings report the stock price went up 4.517%.
Which hedge fund is a major shareholder of Halozyme Therapeutics?
Among the largest hedge funds holding Halozyme Therapeutics’s share is Driehaus Capital Management LLC. It holds Halozyme Therapeutics’s shares valued at 19M.
---
Halozyme Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.57 (47.89% Upside)
$56.57 (47.89% Upside)
Blogger Sentiment
Bullish
GB:0J2O Sentiment 100%
Sector Average 68%
Sector Average 68%
Insider Transactions
Sold Shares
Worth $874.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.34%
12-Months-Change
Fundamentals
Return on Equity
105.22%
Trailing 12-Months
Asset Growth
1.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
---
---